JULIA TIZUE FUKUSHIMA
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
14 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 14
conferenceObject Expression of ERCC1 protein (excision repair cross complementing group 1) in patients with invasive carcinoma of the uterine cervix (CC) undergoing definitive chemoradiation (CR)(2012) CAIRES, Inacelli Queiroz de Souza; CAIRES-LIMA, Rafael; COLOMBO, Renata; RAMOS, Clarissa C. A.; MACHADO, Karime Kalil; SIQUEIRA, Sheila Aparecida Coelho; CARVALHO, Heloisa de Andrade; FUKUSHIMA, Julia Tizue; ADRA, Thais Rodrigues; HOFF, Paulo M.; ESTEVEZ-DIZ, Maria Del PilarBackground: CC is the leading cause of cancer death among women in developing countries. ERCC1 protein participates in DNA repair through the nucleotide excision repair pathway, involved in resistance to platinum-based chemotherapy. Its value as a predictive marker of tumor response to treatment, progression or death is still unknown. We evaluated ERCC1 protein expression and clinical variables as a predictive marker of progression-free survival (PFS) and overall survival (OS) in patients (pts) with CC submitted to CR. Methods: Retrospective data analysis of pts with histological diagnosis of CC, treated with CR between 2004-2009. Platinum-based chemotherapy was administered weekly (x6) concurrent to external beam radiotherapy (EBRT) to the pelvis (39.6 – 45.0 Gy), parametrial boost (14.0 – 20.0 Gy) when indicated and high-dose rate brachytherapy (HDR) (28.0 – 30.0 Gy). ERCC1 expression was assessed by immunohistochemistry (IHC). Results: We analyzed 75 pts, median age was 55 years (range 24-76), the performance status (PS) was 0 or 1 at baseline in 50 pts (66%) and 63 had squamous histology (84%). Thirty-two were stage IIB (43%) and 19 were IIIB (25%). Sixty-five patients received cisplatin 40mg/m2/w (87%) and 9, carboplatin AUC2/w (12%), median of 6 cycles (range 2-9). Median RT and HDR doses were 59.4 Gy (range 40.4 to 60.3) and 28.0 Gy (range 14.0 – 37.5), respectively. Thirty-two pts were available by ERCC1 IHC and all expressed the marker. Median PFS and OS were 35.5 (95% CI – 13.8 - 57.6) and 81 (95% CI- 21.2 - 140.8) months, respectively. In multivariate analysis, receiving < 6 chemotherapy cycles and baseline Hb <10.0 were correlated with disease progression and death, HR 0.302; p 0.011 (95% CI- 0.012-0.762) and HR 0.6; p 0.00 (95% CI- 0.474 – 0.760), respectively. PS at baseline did not correlate with PFS or OS, HR 0.985; p 0.614 (95% CI 0.930 – 1.044). Conclusions: In this population, since all pts expressed the protein, ERCC1 expression couldn't discriminate patients who most benefit from CR. Interestingly, a minimum of 6 chemotherapy cycles and a baseline Hb ≥ 10.0 seem to have a prognostic value.conferenceObject Economic analysis of platelet aggregability-guided surgical revascularization compared with standard of care in ACS patients: subanalysis from PLAT-CABG randomized clinical trial(2020) NAKASHIMA, C. A. K.; DALIAN, L. A. O.; LISBOA, L. A. F.; JATENE, F. B.; SOEIRO, A. M.; NAJJAR, L. A.; SILVA, B. A.; DORNAS, C. J. C. B.; DALCOQUIO, T. F.; FURTADO, R. H. M.; BARACIOLI, L. M.; FUKUSHIMA, J. T.; GURBEL, P. A.; GIUGLIANO, R. P.; NICOLAU, J. C.conferenceObject A phase III, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of pregabalin in the prevention and reduction of oxaliplatin-induced painful neuropathy (PreOx)(2015) ANDRADE, Daniel Ciampi de; TEIXEIRA, Manoel Jacobsen; GALHARDONI, Ricardo; FERREIRA, Karine A. S. L.; MALIENO, Paula Braz; SCISCI, Nathalia; RIECHELMANN, Rachel Pimenta; TEIXEIRA, William G. J.; SARAGIOTTO, Daniel Fernandes; SILVA, Valquiria Aparecida; RAICHER, Irina; CASTRO, Isac de; PARRAVANO, Daniella; FUKUSHIMA, Julia Tizue; LEFAUCHEUR, Jean-Pascal; BOUHASSIRA, Didier; MACARENCO, Ricardo Silvestre e Silva; MELLO, Evandro Sobroza de; HOFF, Paulo MarceloconferenceObject Evaluation of Late Cardiotoxicity in Lymphoma Survivors(2017) LIGUORI, Thiago; GALAS, Filomena R.; SANTOS, Marilia H.; ALMEIDA, Juliano P. de; FUKUSHIMA, Julia T.; MENEGUETTI, Claudio; PEREIRA, Juliana; BELESSO, Marcelo; ROCHA, Wanderson; HAJJAR, Ludhmila A.conferenceObject In-hospital mortality prediction by American Society of Anesthesiology and POSSUM score in patients with cancer undergoing abdominal surgery(2012) SIMOES, Claudia Marquez; CARVALHO, Maria Jose; LUDHMILA, Carmona; HAJJAR, Abrahao; REGINA, Filomena; GALLAS, Barbosa; FUKUSHIMA, Julia TizueIntroduction: Preoperative evaluation and risk stratification is essential to perioperative planning. There are multiple risk scores applied to predict different outcomes. However, specific populations as patients with cancer may have specific risk factors, so it is needed to evaluate if global risk scoresas ASA and POSSUM or P POSSUM are able to assist the surgical team. Objective: To retrospectively assess the value of the ASA classification (American Society of Anesthesiology), POSSUM (Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity), and Porthsmouth POSSUM in prediction of hospital mortality in patients with cancer undergoing abdominal surgery. Methods: Three hundred and thirteen patients who under-went three hundred and nineteen oncologic abdominal surgeries were evaluated using ASA, POSSUM and Porthsmouth-POSSUM in relation to hospital mortality. The variables observed were: age, gender, ASA classification, pul- monary diseases, cardiovascular diseases, preoperative sys-tolic arterial pressure and cardiac rate, Glasgow scale, urea, potassium, sodium, hemoglobin, white cell count, number of simultaneous surgical procedures, observed blood losses, peritoneal contamination, oncological disease and dissemination, elective, emergent or urgent surgery, intensive care support and hospital mortality. Results: The overall hospital mortality rate was 5.59%. These results showed that POSSUM over predicted in-hospital deaths when compared to American Society of Anesthesiologists classification (relative risk, 0.55; P=.07) and Porths- mouth POSSUM (relative risk, 0,43; P=.0007) didn’t equally correspond to ASA predicted perioperative mortality. All evaluated scores didn’t equally predict observed mortality as the standardized mortality rate was 2.25 for ASA classification, 0.4 for POSSUM and 0.8 for P-POSSUM. Conclusion: The ASA classification, POSSUM and P POSSUM scores were not useful in predicting perioperative mortality for patients with cancer submitted to abdominal surgeries. It is needed to evaluate specific populations to adjust the existing perioperative prediction scores to serve as objective methods to assist the surgical team in classifying patients into risk groups with different probabilities of perioperative complications. ASA classification is based mainly on subjective clinical judgments and probably POSUUM and P-POSSUM need to have the equations balanced to specific populations.conferenceObject Platelet aggregability evaluation in patients with acute coronary syndromes scheduled for coronary artery bypass graft. The PLAT-CABG study(2019) NAKASHIMA, C. A. K.; DALLAN, L. A. O.; LISBOA, L. A. F.; HAJJAR, L. A.; SOEIRO, A. M.; SILVA, B. A.; COSTA, M. S. S.; DORNAS, C. J. C. B.; DALCOQUIO, T. F.; FURTADO, R. H. M.; BARACIOLI, L. M.; FUKUSHIMA, J. T.; GURBEL, P. A.; GIUGLIANO, R. P.; NICOLAU, J. C.conferenceObject Carboplatin-based chemoradiotherapy in advanced cervical cancer: An alternative to cisplatin-based regimen?(2014) SEBASTIAO, Ana Morals; ROCHA, Lucila Soares Da Silva; GIMENEZ, Rodrigo Darouche; CAIRES, Inacelli Queiroz De Souza; SILVA, Samantha Cabral Severino Da; BARROS, Laryssa Almeida Borges de; FUKUSHIMA, Julia Tizue; MIRANDA, Vanessa Costa; ABDO FILHO, Elias; FREITAS, Daniela; ESTEVEZ-DIZ, Maria Del PilarconferenceObject VASOPRESSIN OR NOREPINEPHRINE IN VASOPLEGIC AFTER CARDIAC SURGERY (YANCS STUDY): A RANDOMIZED, DOUBLE-BLIND AND CONTROLLED STUDY(2014) HAJJAR, L. A.; VINCENT, J. L.; RHODES, A.; GALAS, F.; FUKUSHIMA, J. T.; OSAWA, E. A.; GRANDE, S. M.; ALMEIDA, J. P.; ZEFFERINO, S.; CAMARA, L.; JATENE, F. B.; FILHO, R. K.conferenceObject PROGNOSTIC FACTORS OF RENAL CELL CARCINOMA WITH VENOUS TUMOR EXTENSION(2016) BEZERRA, Regis; CORDEIRO, Mauricio; CASERTA, Giovanna; LINS, George; FUKUSHIMA, Julia; NAHAS, WilliamconferenceObject Chemotherapy in the intensive care unit patient: A friend or a foe?(2014) HAJJAR, Ludhmila A.; PARK, Clarice H.; FUKUSHIMA, Julia Tizue; ALMEIDA, Juliano; OSAWA, Eduardo A.; NAKAMURA, Rosana; NAGAOKA, Danielle; GALAS, Filomena; ESTEVEZ-DIZ, Maria Del Pilar